Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Mar 6;14:1145797. doi: 10.3389/fendo.2023.1145797

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2023 Zhao, Zhang, Gao, Chi, Zhang, Xia, Cheng and Liu

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Analysis of treatment outcomes between the high-risk and low-risk groups. (A) TIDE analysis between the high-risk and low-risk groups. (B, C) Comparison of the relative distribution of immune scores (IPS) between the high-risk and low-risk groups. (D) Correlation of risk scores with ICB response characteristics and each step of the tumor-immune cycle. (E) Sensitivity to Tozasertib, Staurosporine, Trametinib, and Sinularin in the high-risk and low-risk groups. *p < 0.05.